Education
About Us
Working with TipRanks
Follow Us
Vaxart Inc (VXRT)
NASDAQ:VXRT
Earnings Data
Report Date
May 20, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.1Last Year’s EPS
-0.14Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 20, 2025
|% Change Since: -19.30%
|Next Earnings Date:May 20, 2025
Earnings Call Sentiment|Neutral
The earnings call presents a balanced view with significant progress in norovirus vaccine development and revenue increase, offset by challenges in the COVID-19 program due to the stop work order.Company Guidance
During the Vaxart Business Update and Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company provided detailed guidance on its ongoing and future initiatives. Vaxart emphasized its commitment to developing next-generation oral pill vaccines, highlighting the progress of its COVID-19 and norovirus programs. They reported a significant award of approximately $460 million for a COVID-19 study, although this was temporarily paused by a stop work order from HHS. Despite this, the sentinel cohort of 400 participants continues to be monitored. The company also initiated a Phase 1 trial for its second-generation oral norovirus vaccine, with plans for potential Phase 2 and Phase 3 trials as early as 2025 and 2026, respectively. Financially, Vaxart ended 2024 with $51.7 million in cash, implementing cost-saving measures to extend its runway into Q4 2025. Revenue for 2024 was $28.7 million, primarily from government contracts and non-cash royalty revenue, marking a significant increase from $7.4 million in 2023. The company is exploring partnerships and non-dilutive funding to further support its endeavors.Increased Revenue
Revenue for 2024 was $28.7 million, a significant increase compared to $7.4 million in 2023, primarily from government contracts related to BARDA and non-cash royalty revenue from sales of Inavir in Japan.
Progress in Norovirus Vaccine Development
Initiated a Phase 1 trial for second-generation oral norovirus vaccine constructs, with promising preclinical data indicating potentially more potent responses compared to the first-generation constructs.
Positive Safety Profile
The norovirus oral vaccine candidate demonstrated a benign safety and tolerability profile consistent with previous studies, with no significant differences in adverse events between the vaccine candidate and placebo.
Publication in Science Translational Medicine
Two articles were published on norovirus studies, highlighting the efficiency of the Vaxart platform in generating mucosal antibody responses and supporting immunogenicity in older adults.
Cash Runway Extended
Implemented measures to reduce expenses, including a workforce reduction, and anticipates cash runway into the fourth quarter of 2025.
---
VXRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
VXRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 20, 2025 | $0.57 | $0.52 | -8.77% |
| Nov 13, 2024 | $0.71 | $0.63 | -11.27% |
| Aug 08, 2024 | $0.63 | $0.58 | -7.94% |
| May 13, 2024 | $0.82 | $0.86 | +4.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Vaxart Inc (VXRT) report earnings?
Vaxart Inc (VXRT) is schdueled to report earning on May 20, 2025, TBA Not Confirmed.
What is Vaxart Inc (VXRT) earnings time?
Vaxart Inc (VXRT) earnings time is at May 20, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VXRT EPS forecast?
VXRT EPS forecast for the fiscal quarter 2025 (Q1) is -0.1.
---